Overview
17-alpha hydroxyprogesterone is a steroid hormone produced mainly by the adrenal glands and, to a lesser extent, by the ovaries, testes, and placenta. It plays an important role in adrenal steroidogenesis and serves as a precursor in the synthesis of cortisol. Measurement of serum 17-OHP is primarily used to evaluate adrenal function and is a key marker in the diagnosis of congenital adrenal hyperplasia, especially due to 21-hydroxylase deficiency. Because its levels reflect adrenal enzyme activity, it is widely used in both neonatal screening and adult endocrine evaluation.
Symptoms
Abnormal 17-OHP levels are associated with symptoms related to excess or deficiency of adrenal hormones. Elevated levels may present with ambiguous genitalia in newborn females, early puberty, acne, hirsutism, menstrual irregularities, and infertility in women. In severe cases, infants may develop salt-wasting crises with dehydration and vomiting. Reduced levels may be associated with features of adrenal insufficiency, such as fatigue, weakness, hypotension, and poor stress tolerance.
Causes
Increased serum 17-OHP is most commonly caused by congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which leads to impaired cortisol synthesis and excess ACTH stimulation. This diverts steroid precursors toward androgen production. Elevated levels may also be seen in adrenal or ovarian tumors, polycystic ovary syndrome, stress, and prematurity in infants.
Reduced 17-OHP levels may occur in rare forms of CAH due to 17-alpha 17-Alpha Hydroxyprogesterone deficiency, primary or secondary adrenal insufficiency, suppression of the hypothalamic-pituitary-adrenal axis by prolonged glucocorticoid therapy, obesity, or certain medications.
Risk Factors
Risk factors for abnormal 17-OHP levels include a family history of congenital adrenal hyperplasia, consanguinity, and genetic mutations affecting adrenal steroid enzymes. Newborns, especially premature infants, are at higher risk of transiently elevated levels. Women with hirsutism, infertility, or menstrual disturbances and individuals with suspected adrenal or ovarian tumors are more likely to require evaluation. Chronic stress and endocrine disorders also influence hormone levels.
Prevention
There is no direct prevention for enzyme-related causes of abnormal 17-OHP, but early detection through neonatal screening helps prevent life-threatening complications of congenital adrenal hyperplasia. Regular monitoring of 17-OHP levels aids in assessing the adequacy of cortisol replacement therapy and long-term disease control. Genetic counseling is important for affected families. Timely diagnosis and appropriate management of underlying adrenal or ovarian conditions help reduce complications and improve quality of life.
